Clinical trials: Psychotic Disorder
Schizophrenia
The Use of Transcranial Electrical Stimulation for Hallucinations
Schizophrenia is a serious mental health disorder that affects approximately 1% of the population. Auditory hallucinations are present in as many as 50-75% of patients with this diagnosis.
- Trial name
- NCT02715765
- Testing
- Transcranial Direct Current Stimulation, Transcranial Random Noise Stimulation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Minnesota
Schizophrenia
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia.
- Trial name
- STAR-1 (NCT00509067)
- Testing
- Galantamine, CDP-choline, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Georgetown University
Schizophrenia
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04860830
- Testing
- Iclepertin
- Where
- 110 sites in United States, Argentina and 16 more
- Volunteers
- 609 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia, Schizoaffective Disorder
Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study
The goal of this study is to use transcranial magnetic stimulation (TMS) to investigate the impact of modulating cerebellar activity on time perception, executive function, and mood and psychotic symptoms in psychosis patients…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder I
- Trial name
- NCT02642029
- Testing
- Excitatory TMS, Inhibitory TMS
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Schizophrenia
Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Results
The primary purpose of this study was to conduct fMRI neuroimaging studies prior to and subsequent to the rTMS intervention. The intent was to ascertain changes in regional brain activation and connectivity that most robustly…
- Trial name
- NCT04548622
- Testing
- Magstim Rapid 2 system triggering Magstim Super Rapid system
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
- Trial name
- NCT00588731
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Schizophrenia, Depression
Quetiapine Extended Release Depression Symptoms
Aim of the study is to assess if the new compound Seroquel XR™ is non-inferior to Risperidone, considered as the reference drug for the treatment of depressive symptoms of schizophrenia.
- Trial name
- ExAttitude (NCT00640562)
- Testing
- Quetiapine Extended Release, Risperidone
- Where
- 21 sites in Italy
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Schizophrenia
Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia
The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of once weekly dosing of zicronapine, compared to daily dosing of zicronapine.
- Trial name
- NCT01377233
- Testing
- Zicronapine open-label lead-in 10 mg daily, Zicronapine 10 mg daily, Zicronapine 20 mg once weekly
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants
The purpose of this study is to evaluate improvement and efficacy of paliperidone extended-release for subjective well-being and drug attitudes of participants, when switching from oral antipsychotics in participants with…
- Trial name
- Power (NCT00784238)
- Testing
- Paliperidone
- Where
- 11 sites in South Korea
- Volunteers
- 289 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizoaffective Disorder, Schizophrenia
Smoking Cessation for Veterans With Severe and Persistent Mental Illness
The investigators have developed an intervention called Behavioral Treatment of Smoking Cessation in SPMI (BTSCS), an innovative intervention that supplements pharmacotherapy and education with contingency management and a…
- Conditions
- Schizoaffective Disorder, Schizophrenia, Affective Psychosis, Bipolar, Affective Disorders, Psychotic
- Trial name
- NCT00960375
- Testing
- BTSCS, StSST
- Where
- 2 sites in United States
- Volunteers
- 179 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Schizoaffective Disorder
Improving Accessibility and Personalization of CR for Schizophrenia
This project will explore adaptations of treatments for schizophrenia, with the goal of optimizing their effectiveness in real-world clinical settings and readiness for broad deployment.
- Trial name
- NCT03576976
- Testing
- Cognitive Remediation
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
Treatment Study for Cognitive Deficits in Schizophrenia
Patients with schizophrenia are characterized by a broad range of neurocognitive abnormalities. These include impairments in attention, including abnormalities in sensory gating; executive function; visual and verbal learning and…
- Trial name
- TURNS (NCT00505076)
- Testing
- MK-0777
- Where
- 8 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of California, Los Angeles
Schizophrenia
PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations
The primary goal of the present study is to evaluate the utility of mGluR5 binding as measured by PET as biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.
- Trial name
- NCT02983058
- Testing
- PET/SPECT Scan, MRI Scan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jeffrey A. Lieberman, MD
Schizophrenia
A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia
The purpose of this study is to evaluate the effectiveness of paliperidone ER for the treatment of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and…
- Trial name
- NCT01577160
- Testing
- Paliperidone ER
- Volunteers
- 353 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Psychosis, Dementia
A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
- Conditions
- Psychosis, Dementia, Aggression, Agitation
- Trial name
- NCT03044249
- Testing
- MP-101
- Where
- 20 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- Mediti Pharma Inc.
Schizophrenia, Schizoaffective Disorder
Building Employment Skills Through Therapy for Veterans
Schizophrenia/Schizoaffective Disorder is associated with serious problems with cognitive skills, social skills, and functional skills (like employment).
- Trial name
- BESTVet (NCT01992913)
- Testing
- integrated Cognitive Behavioral Therapy, Usual Care, Computerized cognitive remediation (CCR)
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia
The purpose of this study is to assess the efficacy and safety of 1.5 mg/day dose of paliperidone Extended Release (ER) as compared with placebo when used to treat patients with schizophrenia.
- Trial name
- NCT00524043
- Testing
- Paliperidone ER
- Where
- 20 sites in United States, India and 1 more
- Volunteers
- 201 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia
The purpose of this study is to assess the safety and tolerability of ziprasidone during long-term open-label administration in adolescents (ages 13-17) with schizophrenia.
- Trial name
- NCT00265382
- Testing
- Ziprasidone oral capsules
- Where
- 68 sites in United States, Colombia and 7 more
- Volunteers
- 221 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Alzheimer Disease
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease…
- Trial name
- NCT02392468
- Testing
- BI 409306 25 mg, BI 409306 50 mg
- Where
- 3 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Modafinil Effects on Cognition in Schizophrenia Patients
Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This includes many types of cognitive dysfunction, such as in attention, memory and language.
- Trial name
- InO (NCT00711464)
- Testing
- modafinil (M1, M2, M4)
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles